

David J. Lederer, MD, MS

Summary

- Associate Professor of Medicine and Epidemiology (in Pediatrics), Columbia University
- Pulmonary Director, Pulmonary & Intensive Care Translational Outcomes Research (PICTOR) Group
- Co-Director, NYP/Columbia Interstitial Lung Disease Program
- Senior Medical Advisor, Education & Awareness, Pulmonary Fibrosis Foundation (20% FTE position)
- NHLBI-funded clinical investigator
 - R01 HL103676 (PI: Lederer), MESA Lung Fibrosis Study
 - Imaging, biomarkers, and genetics of subclinical interstitial lung disease
 - R01 HL114626 (multi-PI: Lederer, Christie), Lung Transplant Body Composition Study
 - Mechanisms linking obesity and acute lung injury after human lung transplantation
- Standing member, IRAP study section, CSR/NIH
- Deputy Editor, *Annals of the American Thoracic Society*
- Editorial Board, *American Journal of Respiratory and Critical Care Medicine*
- Statistical Editorial Board, *Thorax*
- Chair, ATS Clinical Problems Assembly Planning Committee
- Member, Research and Scientific Advisory Board, American Lung Association
- Member, SRTR Technical Advisory Committee (STAC)
- Patient Education Blog: <http://www.pfdoc.org>
- On [Facebook](#) and Twitter [@davidlederer](#)

Date of Preparation of CV

July 31, 2015

Contact information

Co-director, Interstitial Lung Disease Program, NYP/Columbia
Columbia University Medical Center
161 Fort Washington Ave, Room 3-321A
Admin Assistant (Susanne): 212-305-8203
Fax: 212-305-8426

Columbia Lung Transplant and Interstitial Lung Disease Research Program
Columbia University Medical Center
622 W 168th Street, PH-9 Center
Research Lead (Tatiana): 212-342-4167

Work Experience: Academic Appointments

03/2014 – Associate Professor of Medicine and Epidemiology (in Pediatrics)
2012 – 2014 Herbert Irving Assistant Professor of Medicine and Epidemiology (in Pediatrics)
Columbia University Medical Center

Lederer CV

Page 2

2008 – 2012 Herbert Irving Assistant Professor of Clinical Medicine (in Pediatrics)
Columbia University Medical Center
07/2006 – 2008 Assistant Professor of Clinical Medicine
Columbia University Medical Center

Work Experience: Hospital, Program, and Foundation appointments

2015 – Director, Educational Materials Development, NIH Rare Lung Disease Consortium
04/2014 – Senior Medical Advisor, Education & Awareness, Pulmonary Fibrosis Foundation
2012 – 15 Associate Medical Director, Lung Transplant Program, NYP/Columbia University
2009 – Co-Director, Interstitial Lung Disease Program, NYP/Columbia University
07/2006 – Assistant Attending Physician, New York Presbyterian Hospital
05/2002 – 05/2003 Assistant Attending Physician, New York Presbyterian Hospital

Traineeship

07/2005 – 06/2006 Research Fellow (T32 HL072739), Columbia University Medical Center
07/2003 – 06/2005 Fellow, Pulmonary and Critical Care, Columbia University Medical Center
05/2002 – 05/2003 Chief Resident, Department of Medicine, Columbia University Medical Center
07/2000 – 05/2002 Resident, Department of Medicine, Columbia University Medical Center
06/1999 – 06/2000 Intern, Department of Medicine, Columbia University Medical Center

Education

07/2005 – 06/2007 M.S., Biostatistics & Patient Oriented Research, Mailman School of Public Health
08/1995 – 06/1999 M.D., SUNY Downstate College of Medicine, Alpha Omega Alpha
01/1990 – 05/1995 B.S., Biology, Adelphi University

Explanation of any gaps in work/training/education:

There are no gaps in my work, training or education

Board Qualifications and Licensure

2012 American Board of Internal Medicine Recertification, Internal Medicine
2006 American Board of Internal Medicine Certification, Critical Care Medicine
2005 American Board of Internal Medicine Certification, Pulmonary Medicine
2002 American Board of Internal Medicine Certification, Internal Medicine
New York State Medical License #218499 (active)

Honors

2014 Harold and Golden Lamport Award for Excellence in Clinical Science Research
2014 Ewig Clinical Scholar (CUMC Teaching Award)
2013 – 15 New York Super Doctors
2012 – 15 Top Doctor: New York Metro Area, US News & World Report/Castle Connolly
2008 – 11 Herbert and Florence Irving Scholar
2008 – 11 Robert Wood Johnson Physician Faculty Scholar
2006 & 2008 American Thoracic Society Travel Awards
2005 Young Investigator Award, American College of Chest Physicians
2005 Fellow Teaching Award, Columbia Presbyterian Medical Housestaff
1999 Harold A. Lyons Award for Excellence in Clinical Medicine, Downstate
1999 State University of New York Chancellor's Award
1998 Alpha Omega Alpha, President, Eta Chapter of New York

Professional organizations, Societies, and Service

Memberships and Positions:

2003- Member, American Thoracic Society
2009- Member, Program committee, Clinical Problems Assembly
2013- Member, Planning committee, Clinical Problems Assembly
2013- Member, ATS Documents Development & Implementation Committee
2015-17 Chair, ATS Clinical Problems Assembly Planning Committee
2011- Fellow, American College of Chest Physicians
2006- Member, International Society of Heart and Lung Transplantation
2012-2014 Member, ISHLT Lung Transplant Selection Guidelines Committee
2014 Member, 2014 ISHLT Program Committee

Consultative:

2015 – 2019 NIH/CSR: Standing member, IRAP study section, Center for Scientific Review
2015– Member, SRTR Technical Advisory Committee (www.srtr.org/Stac)
02/2015 NIH/NHLBI MPOR-MA study section: K23, K24, K25 Career Development Award
11/2014 VA-ORD RR&D Small Projects in Rehabilitation Research (SPiRE) (I21), RFA: RX-14-009
10/2014 NIH/NHLBI ZHL1 CSR-X (O1) 1: K23, K24, K25 Career Development Award
09/2014 NIH/CSR: IRAP *ad hoc* reviewer (R01/R03)
07/2014 NIH/CSR ZRG1 RPHB-S (02) M: Member Conflict: Behavioral Interventions, Obesity, and Chronic Pain (R01)
06/2014 NIH/NHLBI ZHL1 CSR-X (O1) 1: K23, K24, K25 Career Development Award
2014 – Senior Medical Advisor, Pulmonary Fibrosis Foundation (20% FTE)
2014 – Member, Research and Scientific Advisory Board, American Lung Association
03/2014 NIH/NHLBI ZRG1 PSE-Q (56): PAR-13-009: Secondary Dataset Analyses in Heart, Lung, and Blood Diseases and Sleep (R21), Mail Reviewer
11/2013 National Health Service (NHS) National Institute for Health Research (NIHR) Clinician Scientist Programme review committee (K equivalent), Mail reviewer.
11/2013 National Health Service (NHS) Scotland, Chief Scientist Office: Experimental and Translational Medicine Research Committee, Mail reviewer: www.cso.scot.nhs.uk
06/2013 NIH/CSR: IRAP *ad hoc* reviewer (R01/R03)
02/2013 NIH/NHLBI SEP: Phase II Clinical Trials of Novel Therapies for Lung Diseases (UM1)
11/2012 NIH/NHLBI ZHL1 CSR-P (F1): Maximizing the scientific value of the NHLBI biologic specimen repository: Scientific opportunities (R21)
02/2012 NIH/NHLBI ZHL1 CSR-F (M1): Mentoring programs to promote diversity in health research (K01/R25)
2012 – 13 Member, NHLBI Workshop, Primary Prevention of Chronic Lung Diseases
2011 – 14 American Lung Association Research Training Fellowship Study Section

Editorial:

2015- Statistical Editorial Board, *Thorax*
2013- Editorial Board, *American Journal of Respiratory and Critical Care Medicine*
2012- Deputy Editor, *Annals of the American Thoracic Society*

Departmental and University Committees:

2013 – Scientific Advisory Committee, Clinical Research Resource, Columbia CTSA
2013 – Founder, Clinical/Epidemiological Research Seminar Series, DOM
2012– Doctoral admissions committee, Department of Epidemiology, Mailman SPH
2012–15 NYP Transplant Executive Quality Council
2011 – POR Advisory Board, Irving Institute/Columbia CTSA
2010– Working Group on Clinical and Epidemiological Research, DOM
2009 Medical student curriculum committee
2006–12 Pulmonary fellow selection committee

Grant Support

Ongoing Research Support

R01 HL103676 (Lederer) 04/15/2011 – 04/14/2016 (NCE)

NIH/NHLBI

Subclinical Interstitial Lung Disease in MESA

The Aims of this project are to validate high attenuation areas (HAA) on CT as a marker of subclinical interstitial lung disease and perform genome wide association and linkage studies of HAA.

Role: PI

R01 HL114626 (Multi-PI: Lederer; Christie) 05/23/2013 – 03/31/2017

NIH/NHLBI

Obesity, Inflammation, and Lung Injury after Lung Transplantation

The Aims of this project are to determine roles of adipose tissue distribution and adipose tissue inflammation in the development of primary graft dysfunction after lung transplantation

Role: PI

R01 HL087115 (Christie) 08/15/2007 – 07/31/2018

NIH/NHLBI

Clinical Risk Factors for Primary Graft Dysfunction

This is a study to identify clinical predictors of primary graft failure after lung transplantation.

Role: Co-Investigator (Columbia site PI)

R01 HL114468 (Hancock) 05/15/2012 – 03/31/2016

NIH/NHLBI

Foxp3+ Treg Cells & Primary Graft Dysfunction in Clinical Lung Tx Recipients

The Aims of this project are to examine role of Treg cells in primary graft dysfunction after lung transplantation.

Role: Co-investigator (Columbia site PI)

T32 HL105323 (J. Bhattacharya) 07/01/2011 – 06/30/2016

Columbia University Training Program in Lung Science

This training grant aims to train postdoctoral scientists pursuing either basic science or translational research in the field of inflammatory lung disease, preparing them for scientific careers in academia.

Role: Executive committee member/mentor

R25 HL105401 (Begg) 09/25/2010 – 07/31/2014

Lederer CV

Page 5

PRIDE/FIRST in CER (Facilitating Independence in Research through the Summer Training in Comparative Effectiveness Research) Diversity Program

This program provides summer training and mentoring in skills essential to conducting comparative effectiveness research (CER), enhancing the career development of faculty and scientists.

Role: Mentor

R25 HL096260 (Begg)

05/15/2009 – 04/30/2014

BEST-DP: Biostatistics Enrichment Summer Training Diversity Program

This program provides research opportunities in biostatistics, cardiovascular disease, and pulmonary disease for individuals who are under- represented in biomedical research.

Role: Mentor

GS-US-322-0207

3/01/2013 - 12/31/2016

Gilead

A Phase 2, Randomized, Double-Blind Placebo-Controlled Multicenter study to assess the efficacy and safety of simtuzumab (GS6624) in subjects with Idiopathic Pulmonary Fibrosis

This is a multicenter clinical trial of simtuzumab, a LOXL2 inhibitor, to treat IPF.

Role: Columbia site PI

Completed Research Support

K23 HL086714 (Lederer)

04/01/2008 – 03/31/2013

NIH/NHLBI

Explaining Racial and Ethnic Disparities in Idiopathic Pulmonary Fibrosis

The major goal of this project is to examine novel predictors of mortality in IPF

Role: PI

General Research Grant

07/01/2012 – 06/30/2013

Pulmonary Fibrosis Foundation

Subclinical Interstitial Lung Disease in MESA: The MESA Lung Fibrosis Study

The Aims of this project are to validate high attenuation areas (HAA) on CT as a marker of subclinical interstitial lung disease and perform genome wide association and linkage studies of HAA.

Role: PI

Physician Faculty Scholar Award (Lederer)

07/01/2008 – 06/30/2011

Robert Wood Johnson Foundation

Explaining Racial and Ethnic Disparities in Idiopathic Pulmonary Fibrosis

The major goal of this project is to examine novel predictors of mortality in idiopathic pulmonary fibrosis

Role: PI

Irving Scholar Award (Lederer)

07/01/2008 – 06/30/2011

Irving Institute for Clinical and Translational Research

Race, Society, and Biology in Pulmonary Fibrosis

The major goal of this project is to examine biological factors that explains variation in survival time in IPF

Role: PI

U01 HL105371 (Choi;Rosas;Garcia)

03/01/2012 – 12/31/2015

NIH/NHLBI

Phase II Study of Inhaled Carbon Monoxide for the Treatment of IPF

The purpose of this study is test the safety and efficacy of inhaled carbon monoxide in IPF

Role: Co-investigator (Columbia site PI)

R01 HL081619 (Christie)

02/15/2007 – 01/31/2013

NIH/NHLBI

Genetics of Primary Graft Dysfunction

This study aims to identify genetic predictors of predict primary graft failure after lung transplant.

Role: Co-Investigator (Columbia site PI)

R21 HL092478 (D'Ovidio)

04/01/2010 – 03/31/2012

Role of SP-A gene polymorphism in lung transplantation

This is a candidate gene study to examine the association between SP-A gene polymorphisms and the risk of bronchiolitis obliterans syndrome in a lung transplant cohort.

Role: Collaborator

R01 HL0828951 (Kawut)

03/01/2006 – 09/30/2010

NIH/NHLBI

A Clinical Trial of Aspirin and Simvastatin in Pulmonary Arterial Hypertension

This is a 2X2 factorial clinical trial of aspirin and simvastatin in pulmonary arterial hypertension. The goal is to study the combination of these drugs in patients with pulmonary arterial hypertension.

Role: Co-Investigator (Columbia site PI)

U01 AI063589 (Shaked)

09/01/2004 – 08/31/2011

NIH/NHLBI

CTOT-03: Molecular profiling and immunomodulatory interventions

This study examines gene expression profiling for the characterization of innate immunity and adaptive immunity pertinent to solid organ transplantation.

Role: Co-Investigator (Columbia site Lung PI)

Irving Pilot Award (Lederer)

07/01/2012 – 06/30/2013

UL1 TR000040: Irving Institute for Clinical and Translational Research

Obesity, Lung Transplantation, and Lung Injury

The major goal of this pilot study is to examine the use of quantitative CT imaging to ascertain adipose tissue distribution in lung transplant candidates.

Role: PI

KL2 RR024157 (Ginsberg)

01/01/2007 – 03/31/2008

NIH/NCRR

Determinants of Racial and Ethnic Disparities in Idiopathic Pulmonary Fibrosis

This study examines the factors that contribute to racial and ethnic disparities in idiopathic pulmonary fibrosis.

Role: K12/KL2 Awardee

T32 HL072739 (Schluger)

07/01/2005 – 06/30/2006

NIH/NHLBI

Training in Translational Lung Research

The major goal of this project is to prepare physician-scientists to conduct translational research in pulmonary medicine.

Role: Trainee

NIH Loan Repayment Award (Lederer)

07/01/2006 – 06/30/2010

Socioeconomic Status and Survival in Idiopathic Pulmonary Fibrosis

This study examines the association between socioeconomic status and survival in patients with idiopathic pulmonary fibrosis.

Role: PI

CTSA Irving Institute Imaging Award (Lederer)

03/01/2009 – 02/28/2011

Irving Institute for Clinical and Translational Research

A pilot study to measure pulmonary endothelial dysfunction using positron emission tomography

The major goal of this project is to examine the reproducibility of extravascular lung water measurement using PET imaging of ¹⁵O-radiotracers in humans.

Role: PI

BI 1199.32

07/01/2011– 01/31/2014

Boehringer-Ingelheim

A 52 week, double-blind, randomized, placebo-controlled trial evaluating the effect of oral BIBF 1120, 150mg twice daily, on annual FVC decline in patients with IPF

This is a multicenter clinical trial of BIBF 1120 to treat IPF.

Role: Columbia site PI

BI 1199.33

04/01/2013– 12/31/2015

Boehringer-Ingelheim

An open label extension study of oral BIBF 1120 in patients with IPF

This is a multicenter open label extension clinical trial of BIBF 1120 to treat IPF.

Role: Columbia site PI

CD-RI-CAT-354-1066

12/04/2012 - 12/31/2015

MedImmune

A Phase 2, Randomized, Dose Ranging Study to Evaluate the Efficacy of Tralokinumab in Adults with Idiopathic Pulmonary Fibrosis

This is a multicenter clinical trial of tralokinumab (an IL-13 antagonist) to treat IPF.

Role: Columbia site PI

GS-US-231-0101

01/01/2009 – 03/31/2011

Gilead Sciences, Inc.

ARTEMIS-IPF: Randomized trial of ambrisentan in early idiopathic pulmonary fibrosis

This is a multicenter clinical trial of ambrisentan to treat IPF.

Role: PI (Columbia site)

Lederer CV

Page 8

GS-US-300-0128

11/01/2009 – 02/01/2011

Gilead Sciences, Inc.

ARTEMIS-PH: Randomized trial of ambrisentan in pulmonary hypertension in idiopathic pulmonary fibrosis

This is a multicenter clinical trial of ambrisentan to treat PH accompanying IPF.

Role: PI (Columbia site)

G050219

08/31/2006 – 06/30/2011

Broncus Technologies, Inc.

EASE: A Randomized Trial of the Exhale® Drug-Eluting Stent in Emphysema

This is a multicenter clinical trial of airway bypass in emphysema.

Role: Co-investigator

CPR-01377

04/01/2009 – 03/31/2011

Spiration, Inc.

SPIRATION 2: A Randomized Trial of the IBV Valve System in Emphysema

This is a multicenter clinical trial of an endobronchial valve for emphysema.

Role: Co-Investigator

IW001-01

04/01/2012– 5/31/2012

ImmuneWorks, Inc.

A Phase One, Open Label, Multi-Dose Study to Evaluate the Safety, Tolerability, and Biologic Effects of Three Doses of IW001 in Patients with Idiopathic Pulmonary Fibrosis (IPF)

This is a multicenter phase 1 clinical trial of oral type V collagen (IW001) to treat IPF.

Role: Columbia site PI

Teaching Experience and Responsibilities

Specific Courses, P&S

The Body: In Health & Disease

Section Director (Pulmonary), 2010-2014

Lecturer, “Interstitial Lung Disease”, 2011-2015

Lecturer, “Ventilation”, “Mechanics and PFTs”, “Gas exchange”, “COPD”, 2011-2014

Small Group Preceptor, 2010-2015

Pulmonary Pathophysiology

Section Director, 2007-2010

Lecturer, “Ventilation and lung mechanics”, 2010

Lecturer, “Interstitial lung disease”, 2008-2010

Lecturer, “COPD”, 2008-2010

Small Group Preceptor, 2006-2010

Epidemiology

Course Director, 2012-2013

Lecturer, “Longitudinal Studies”, “Case-control studies”, “Confounding and Interaction”, 2012-2013

Small Group Preceptor, 2008-2013

Lederer CV

Page 9

Clinical Contact during the lab years

Preceptor, 2010-2011

Physical Diagnosis

Preceptor, 2006 and 2008

Clinical Practice

Preceptor, 2006-2008

General Teaching Activities:

2014 "Interstitial Lung Disease", Lecture, Cardiothoracic Resident Curriculum
2013-15 "Clinical Epidemiology" Lecture, Pulmonary Fellowship Curriculum
2013 "Lung Transplantation" Lecture, Medical Housestaff Curriculum
2011 – 2013 "Interstitial Lung Disease" Lecture, Medical Housestaff Curriculum
2009, 2013 "Lung Transplantation" Lecture, Pediatric Pulmonary Fellows
2008 – 2014 Journal Club leader, Division of Pulmonary, Allergy, and Critical Care
2006 – 2015 Lung transplant inpatient attending
2015-07-31 Pulmonary Consultation attending
2006 Small group preceptor, Junior medicine resident retreat
2006 – Resident morning report attending
2006 – Harkness (outpatient) report attending

Columbia University, Mailman School of Public Health

2009 BEST Diversity Program mentor (Mentee: Amy Giunta, BS)
2011 FIRST in CER Program mentor (Mentee: Hilary Robbins, MD, Columbia Univ.)
2012 BEST Diversity Program mentor (Mentees: Imaani Easthausen, Isaac Quintanilla)
2013 PRIDE/FIRST in CER Program mentor (Titi Ilori, MD, Emory University)
2014 BEST/CSIBS Program Mentor (Mentees: Wendi & Jerson)
2013 Faculty Advisor to Kate Doyle (MPH candidate, Epidemiology)
2014 Faculty Advisor to Melinda Eller (MPH candidate, Epidemiology)
2014 Guest Lecturer Jan 28, 2014, Splines and other non-linear models, Epidemiology 6,
Course Director: Gina Lovasi, PhD

Columbia University, Continuing Medical Education

2009 – 13 "COPD", Columbia University Annual Internal Medicine Review
2013 "Interstitial lung disease in 2014: Best practice in diagnosis and management",
Columbia University, Update in Pulmonary & Critical Care 2013; Dec 13, 2013

Professional Society/NIH/Academic/Non-Profit Committees, Workshops, & Positions

2009 – Program Committee, American Thoracic Society, Clinical Problems Assembly
2009 – Abstract reviewer, ATS International Conference
2010 – Abstract reviewer, ISHLT Annual Meeting
2010 – Lung Transplant Outcome Group (LTOG) Ancillary Study Committee
2011 Program Committee, RWJ Physician Faculty Scholar 2011 National Mtg
2011 – POR Advisory Board, Irving Institute/Columbia CTSA
2012 – 13 Member, ISHLT Lung Transplant Selection Guidelines Working Group
2012 – 13 Member, NHLBI Workshop, Primary Prevention of Chronic Lung Diseases

Lederer CV

Page 10

2013 – Scientific Advisory Committee, Clinical Research Resource, Columbia CTSA
2013 – 14 Member, 2014 ISHLT Program Committee
2013 – Member, ATS Document Development & Implementation Committee
2013 – Planning Committee, ATS, Clinical Problems Assembly
2014 – Member, Research and Scientific Advisory Board, American Lung Association
2014 – PILOT for IPF Steering Committee, France Foundation
2014 – Senior Medical Advisor, Pulmonary Fibrosis Foundation (20% FTE)
2015– Member, SRTR Technical Advisory Committee

Industry Activity

2010 Advisory Board on Idiopathic Pulmonary Fibrosis, Gilead, Inc.
2011 Advisory Board on Pulmonary Arterial Hypertension, Gilead, Inc.
2011 – 14 Steering Committee, ASCEND trial of pirfenidone for IPF, Intermune, Inc.
2012 – Scientific Advisory Board on Lung Transplantation, ImmuneWorks Inc.
2012 – Central Advisory/Steering Committee, RAINIER trial of simtuzumab for IPF, Gilead
2013 – 14 Clinical Advisory Board, Intermune, Inc.
2014 – Consultant, XVIVO, Inc., clinical trials of *ex vivo* lung perfusion in lung transplantation
2014 – Consultant, Boehringer-Ingelheim, IPF clinical trials
2014 Member, IPF Training Steering Committee, Intermune, Inc.
2015 – Advisory Board, RSV/lung transplantation, Gilead, Inc.

Media/Social Media appearances

Radio Media Tour for PFF (Nov 21 and 24, 2014 with various air dates)
The Morning Show, with Jim Berni (WNPQ-FM, Akron, OH)
The Morning Show with Nelson Hunter (WVNU-FM, Cincinnati, OH)
Dan & Mike in the Morning (WBEX-AM, Columbus, OH)
The Lunch Counter (WYYZ-AM, Atlanta)
Page Two (WDBL-AM, Nashville, TN)
It's Your Health (National)
Breakfast with Bob (WAMV-AM, Roanoke, VA)
Ask Mom RN Show (National)
Ron & Corey Morning Show (KLTF-AM, Minneapolis, MN)
News Segment (KETR-AM, Dallas TX)
Good Mornings (WFIN, Toledo, OH)
News Segment (KULP-AM, Houston TX)
The 2-o'clock Show (KPQ-AM, Seattle WA)
Driving you Home with JR (WKUL-FM, Birmingham, AL)
AM Ocala Live (WOCA-AM, Orlando, FL)
The Morning Report (KSYS-AM, Kansas City, MO)
Community Spotlight (KXEN-AM, St. Louis, MO)

www.pfdoc.org Founder, Patient Education Website & Blog about Pulmonary Fibrosis

2013 PILOT Mini-Symposium: http://www.pilotforipf.org/2013_mini_symposium.php

@davidlederer Twitter account

- May 18, 2014 Expert Commentary on pirfenidone/nintedanib in IPF, Health Day, “2 Drugs Offer Hope for Fatal Lung Disease”, <http://bit.ly/1rH3AiT>
- Dec 16, 2013 Expert Commentary on Lung Transplantation. Reuters Health/Medscape, “Similar Lung Transplant Waitlist Mortality for Children and Adults”, Will Boggs MD, <http://www.medscape.com/viewarticle/817911>
- July 27, 2011 Expert Commentary on Research in Lung Transplantation. National Public Radio, Connecticut affiliate station WNPR, “Four Failing Lungs”, *Where We Live*, Host: John Dankosky. <http://www.yourpublicmedia.org/content/wnpr/where-we-live-four-failing-lungs>
- Feb. 28, 2008 Expert Commentary on Racial Disparities in Lung Transplantation. WOL 1450 AM, Washington D.C., Host: Darrell Greene

Patents & Inventions

None

Publications

Original, Peer-reviewed articles

1. *Singer JP, Diamond JM, Gries CJ, McDonnough J, Blanc PD, Shah R, Dean MY, Hersh B, Wolters PJ, Tokman S, Arcasoy SM, Ramphal K, Greenland JR, Smith N, Heffernan P, Shah L, Shrestha P, Golden JA, Blumenthal N, Huang D, Sonett J, Hays S, Oyster M, Katz PP, Robbins H, Brown M, Leard LE, Kukreja J, Bacchetta M, Bush E, D'Ovidio F, Rushefski M, Raza K, Christie JD, **Lederer DJ**. Frailty Phenotypes, Disability, and Outcomes in Adult Candidates for Lung Transplantation. *Am J Respir Crit Care Med*. *In press*
2. Esposito DB, Lanes S, Donneyong M, Holick CN, Lasky JA, **Lederer D**, Nathan SD, O'Quinn S, Parker J, Tran TN. Idiopathic Pulmonary Fibrosis in US Automated Claims: Incidence, Prevalence and Algorithm Validation. *Am J Respir Crit Care Med* (in press)
3. Shah RJ, Diamond JM, Cantu E, Flesch J, Lee JC, **Lederer DJ**, Lama VN, Orens J, Weinacker A, Wilkes DS, Roe D, Bhorade S, Wille KM, Ware LB, Palmer SM, Crespo M, Demissie E, Sonnet J, Shah A, Kawut SM, Bellamy SL, Localio AR, Christie J. Objective Estimates Improve Risk Stratification for Primary Graft Dysfunction after Lung Transplantation. *Am J Transplant* (in press)
4. Oelsner EC, Hoffman EA, Folsom AR, Carr JJ, Enright PL, Kawut SM, Kronmal R, **Lederer D**, Lima JA, Lovasi GS, Shea S, Barr RG. Association between emphysema-like lung on cardiac computed tomography and mortality in persons without airflow obstruction: a cohort study. *Ann Intern Med*. 2014 Dec 16;161(12):863-73. doi: 10.7326/M13-2570.
5. **Lederer DJ**, Bradford WZ, Fagan EA, Glaspole I, Glassberg MK, Glasscock KF, Kardatzke D, King TE Jr, Lancaster LH, Nathan SD, Pereira CA, Sahn SA, Swigris JJ, Noble PW. Sensitivity Analyses of the Change in Forced Vital Capacity in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis. *Chest* 2015;148(1):196-01.
6. Matura LA, Ventetuolo CE, Palevsky HI, **Lederer DJ**, Horn EM, Mathai SC, Pinder D, Archer-Chicko C, Bagiella E, Roberts KE, Tracy RP, Hassoun PM, Girgis RE, Kawut SM. Interleukin-6 and Tumor

Necrosis Factor- α Are Associated with Quality of Life-Related Symptoms in Pulmonary Arterial Hypertension. *Ann Am Thorac Soc* 2015 Mar;12(3):370-5.

7. *Bernstein EJ, Peterson ER, Sell JL, D'Ovidio F, Arcasoy SM, Bathon JM, Lederer DJ. Survival of adults with systemic sclerosis following lung transplantation: A nationwide cohort study. *Arthritis Rheumatol* 2015; 67(5):1314-22.
8. *Singer JP, Peterson ER, Snyder ME, Katz PP, Golden JA, D'Ovidio F, Bacchetta M, Sonett JR, Kukreja J, Shah L, Robbins H, Van Horn K, Shah RJ, Diamond JM, Wickersham N, Sun L, Hays S, Arcasoy SM, Palmer SM, Ware LB, Christie JD, **Lederer DJ**. Body Composition and Mortality after Adult Lung Transplantation in the United States. *Am J Respir Crit Care Med* 2014;190(9):1012-21.
9. Sayah DM, Mallavia B, Liu F, Ortiz-Muñoz G, Cadrillier A, DerHovanessian A, Ross DJ, Lynch JP 3rd, Sagar R, Ardehali A; **Lung Transplant Outcomes Group Investigators**, Ware LB, Christie JD, Belperio JA, Looney MR. Neutrophil extracellular traps are pathogenic in primary graft dysfunction after lung transplantation. *Am J Respir Crit Care Med* 2015 Feb 15;191(4):455-63.
10. **Lederer DJ**, Philip N, Rybak D, Arcasoy SM, Kawut SM. Intravenous Immunoglobulin for Hypogammaglobulinemia after Lung Transplantation: A Randomized Crossover Trial. *PLoS One* 2014 Aug 4;9(8):e103908
11. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR; INPULSIS Trial Investigators (**Named Collaborator**). Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. *N Engl J Med*. 2014 May 29;370(22):2071-82.
12. Loth DW, Artigas MS, Gharib SA, Wain LV, Franceschini N, Koch B, Pottinger TD, Smith AV, Duan Q, Oldmeadow C, Lee MK, Strachan DP, James AL, Huffman JE, Vitart V, Ramasamy A, Wareham NJ, Kaprio J, Wang XQ, Trochet H, KŠhšnen M, Flexeder C, Albrecht E, Lopez LM, de Jong K, Thyagarajan B, Alves AC, Enroth S, Omenaas E, Joshi PK, Fall T, Vi-uela A, Launer LJ, Loehr LR, Fornage M, Li G, Wilk JB, Tang W, Manichaikul A, Lahousse L, Harris TB, North KE, Rudnicka AR, Hui J, Gu X, Lumley T, Wright AF, Hastie ND, Campbell S, Kumar R, Pin I, Scott RA, PietilŠinen KH, Surakka I, Liu Y, Holliday EG, Schulz H, Heinrich J, Davies G, Vonk JM, Wojczynski M, Pouta A, Johansson A, Wild SH, Ingelsson E, Rivadeneira F, VŠlzke H, Hysi PG, Eiriksdottir G, Morrison AC, Rotter JI, Gao W, Postma DS, White WB, Rich SS, Hofman A, Aspelund T, Couper D, Smith LJ, Psaty BM, Lohman K, Burchard EG, Uitterlinden AG, Garcia M, Joubert BR, McArdle WL, Musk AB, Hansel N, Heckbert SR, Zgaga L, van Meurs JB, Navarro P, Rudan I, Oh YM, Redline S, Jarvis DL, Zhao JH, Rantanen T, O'Connor GT, Ripatti S, Scott RJ, Karrasch S, Grallert H, Gaddis NC, Starr JM, Wijmenga C, Minster RL, **Lederer DJ**, Pekkanen J, Gyllensten U, Campbell H, Morris AP, GlŠser S, Hammond CJ, Burkart KM, Beilby J, Kritchevsky SB, Gudnason V, Hancock DB, Williams OD, Polasek O, Zemunik T, Kolcic I, Petrini MF, Wjst M, Kim WJ, Porteous DJ, Scotland G, Smith BH, Viljanen A, Helišvaara M, Attia JR, Sayers I, Hampel R, Gieger C, Deary IJ, Boezen HM, Newman A, Jarvelin MR, Wilson JF, Lind L, Stricker BH, Teumer A, Spector TD, MelŽn E, Peters MJ, Lange LA, Barr RG, Bracke KR, Verhamme FM, Sung J, Hiemstra PS, Cassano PA, Sood A, Hayward C, Dupuis J, Hall IP, Brusselle GG, Tobin MD, London SJ. Genome-wide association analysis identifies six new loci associated with forced vital capacity. *Nat Genet*. 2014 46(7):669-77.
13. Shah RJ, Emtiazjoo AM, Diamond JM, Smith PA, Roe DW, Wille KM, Orens JB, Ware LB, Weinacker A, Lama VN, Bhorade SM, Palmer SM, Crespo M, **Lederer DJ**, Cantu E, Eckert GJ, Christie JD, Wilkes

- DS. Plasma complement levels are associated with primary graft dysfunction and mortality after lung transplantation. *Am J Respir Crit Care Med*. 2014 Jun 15;189(12):1564-7
14. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, **Lederer DJ**, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW; the ASCEND Study Group. A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. *N Engl J Med* 2014;370(22):2083-92.
 15. Diamond JM, Akimova T, Kazi A, Shah RJ, Cantu E, Feng R, Levine MH, Kawut SM, Meyer NJ, Lee JC, Hancock WW, Aplenc R, Ware LB, Palmer SM, Bhorade S, Lama VN, Weinacker A, Orens J, Wille K, Crespo M, **Lederer DJ**, Arcasoy S, Demissie E, Christie JD; for the Lung Transplant Outcomes Group. Genetic Variation in Prostaglandin E2 Pathway is Associated with Primary Graft Dysfunction. *Am J Respir Crit Care Med* 2014;189(5):567-75.
 16. *Baldwin MR, Reid MC, Westlake AA, Wunsch H, Rowe JW, Granieri EC, Dam T, Rabinowitz D, Goldstein NE, Maurer MS, **Lederer DJ**. The Feasibility of Measuring Frailty to Predict Disability and Mortality in Older Medical-ICU Survivors. *J Crit Care* 2014;29(3):401-8.
 17. Shah RJ, Wickersham N, **Lederer DJ**, Palmer SM, Cantu E, Diamond JM, Kawut SM, Lama VN, Bhorade S, Crespo M, Demissie E, Sonett J, Wille K, Orens J, Weinacker A, Shah P, Arcasoy S, Wilkes DS, Christie JD, Ware LB. Pre-operative plasma club (clara) cell secretory protein levels are associated with primary graft dysfunction after lung transplantation. *Am J Transplant* 2014;14(2):446-52.
 18. D'Ovidio F, Kaneda H, Chaparro C, Mura M, **Lederer D**, Di Angelo S, Takahashi H, Gutierrez C, Hutcheon M, Singer LG, Waddell TK, Floros J, Liu M, Keshavjee S. Pilot Study Exploring Lung Allograft Surfactant Protein A (SP-A) Expression in Association With Lung Transplant Outcome. *Am J Transplant* 2013; 13(8):2130-6.
 19. Baldwin MR, **Lederer DJ**, Bach P, et al. High Burden of Palliative Needs Among Older ICU Survivors Transferred to Post-Acute Care Facilities: A Single Center Study. *Ann Am Thorac Soc* 2013; 10(5):458-65.
 20. *Baldwin MR, Peterson ER, Easthausen I, Quintanilla I, Colago E, Sonett JR, D'Ovidio F, Costa J, Diamond JM, Christie JD, Arcasoy SM, **Lederer DJ**. Donor age and early graft failure after lung transplantation: a cohort study. *Am J Transplant* 2013;13(10):2685-95
 21. Aramini B, Kim C, Diangelo S, Petersen E, **Lederer DJ**, Shah L, Robbins H, Floros J, Arcasoy SM, Sonett JR, D'Ovidio F. Donor Surfactant Protein D (SP-D) Polymorphisms Are Associated With Lung Transplant Outcome. *Am J Transplant* 2013;13(8):2130-6.
 22. Kato TS, Cheema F, Yang J, Kawano Y, Takayama H, Naka Y, Farr M, **Lederer DJ**, Baldwin MR, Jin Z, Homma S, Mancini DM, Schulze PC. Preoperative Serum Albumin Levels Predict One-Year Postoperative Survival of Patients Undergoing Heart Transplantation. *Circ Heart Fail* 2013; 6(4):785-91.
 23. Cantu E, **Lederer DJ**, Meyer K, Milewski K, Suzuki Y, Shah RJ, Diamond JM, Meyer NJ, Tobias JW, Baldwin DA, Van Deerlin VM, Olthoff KM, Shaked A, Christie JD; for the CTOT Investigators. Gene Set Enrichment Analysis Identifies Key Innate Immune Pathways in Primary Graft Dysfunction After Lung Transplantation. *Am J Transplant* 2013;13(7):1898-904.
 24. Patel NM, Kawut SM, Arcasoy SM, Jelic S, **Lederer DJ**, Borczuk AC. Pulmonary arteriole gene expression signature in idiopathic pulmonary fibrosis. *Eur Respir J* 2013;41(6):1324-30

25. Tsuang WM, Vock DM, Finlen-Copeland CA, **Lederer DJ**, Palmer SM. An acute change in lung allocation score and survival after lung transplantation: A cohort study. *Ann Intern Med* 2013;158(9): 650-7.
26. Raghu G, Behr J, Brown KK, Egan JJ, Kawut SM, Flaherty K, Martinez FJ, Nathan SD, Wells AU, Collard HR, Costabel U, Richeldi L, de Andrade J, Khalil N, Morrison LE, **Lederer DJ**, Shao L, Pedersen PS, Montgomery AB, Chien JW, O'Riordan TG, and the ARTEMIS IPF investigators. ARTEMIS-IPF: Treatment of Idiopathic Pulmonary Fibrosis with Ambrisentan, a Selective Antagonist of the Endothelin A Receptor: A Randomized Trial. *Ann Intern Med* 2013;158(9): 641-9.
27. Baldwin MR, Narain WR, Wunsch H, Schluger NW, Cooke JT, Maurer MS, Rowe JW, **Lederer DJ**, Bach PB. A prognostic model for 6-month mortality in elderly survivors of critical illness. *Chest* 2013;143(4):910-9.
28. Diamond JM, Lee JC, Kawut SM, Shah RJ, Localio AR, Bellamy SL, **Lederer DJ**, Cantu E, Kohl BA, Lama VN, Borhade SM, Crespo M, Demissie E, Sonett J, Wille K, Orens J, Shah AS, Weinacker A, Arcasoy S, Shah PD, Wilkes DS, Ware LB, Palmer SM, Christie JD; Lung Transplant Outcomes Group. Clinical risk factors for primary graft dysfunction after lung transplantation. *Am J Respir Crit Care Med* 2013;187(5):527-34.
29. Shah RJ, Diamond JM, Cantu E, Lee J, **Lederer DJ**, Lama V, Orens J, Weinacker A, Wilkes D, Borhade S, Wille K, Ware L, Palmer S, Crespo M, Localio AR, Demissie EJ; Kawut SM, Bellamy S, Christie JD. Latent class analysis identifies distinct phenotypes of primary graft dysfunction after lung transplantation. *Chest* 2013;144(2):616-22.
30. Diamond JM, Porteous MK, Cantu E, Meyer NJ, Shah RJ, **Lederer DJ**, Kawut SM, Lee J, Bellamy S, Palmer SM, Lama VN, Borhade S, Crespo M, Demissie E, Wille K, Orens J, Shah PD, Weinacker A, Weill D, Arcasoy S, Wilkes DS, Ware LB, and Christie JD for the Lung Transplant outcomes Group. Elevated Plasma Angiotensin-2 Levels and Primary Graft Dysfunction after Lung Transplantation. *PLoS One* 2012;7(12):e51932.
31. Shah RJ, Diamond JM, **Lederer DJ**, Arcasoy SM, Cantu EM, Demissie EJ, Kawut SM, Kohl B, Lee JC, Sonett J, Christie JD, Ware LB. Plasma monocyte chemoattractant protein-1 levels at 24 hours are a biomarker of primary graft dysfunction after lung transplantation. *Transl Res* 2012;160(6):435-42.
32. Ventetuolo CE, Lima JAC, Barr RG, Bristow MR, Bagiella E, Chahal H, Kizer JR, **Lederer DJ**, Blumke DA, Kawut SM. The renin-angiotensin system and right ventricular structure and function: The MESA-Right Ventricle Study. *Pulm Circ* 2012; 2(3):379-86.
33. Diamond JM, Meyer NJ, Feng R, Rushefski M, **Lederer DJ**, Kawut SM, Lee JC, Cantu E, Shah R, Lama VN, Borhade S, Crespo M, Demissie E, Sonett J, Wille K, Orens J, Weinacker A, Weill D, Arcasoy S, Shah PD, Belperio JA, Wilkes D, Ware LB, Palmer SM and Christie JD for the Lung Transplant Outcomes Group. Variation in PTX3 is associated with primary graft dysfunction after lung transplantation. *Am J Respir Crit Care Med* 2012;86(6):546-552.
34. Shah RJ, Bellamy SL, Localio AR, Wickersham N, Diamond JM, Weinacker A, Lama VN, Borhade S, Belperio JA, Crespo M, Demissie EJ, Kawut SM, Wille KM, **Lederer DJ**, Lee JC, Palmer SM, Orens J, Reynolds J, Shah A, Wilkes DS, Ware LB, Christie JD. A panel of lung injury biomarkers enhances the definition of primary graft dysfunction (PGD) after lung transplantation. *J Heart Lung Transplant* 2012;31(9):942-9.

35. *Ventetuolo C, Kawut SM, **Lederer DJ**. Plasma endothelin-1 and vascular endothelial growth factor levels and their relationship to hemodynamics in idiopathic pulmonary fibrosis. *Respiration* 2012;84(4):299-305.
36. Weingarten JA, **Lederer DJ**, Ozturk E, Milite F, Mooney AM, Thomashow BM, Basner RC. A comparison of single breath and re-breathe diffusing capacity in emphysema patients and controls. *Respir Physiol Neurobiol* 2012;183(1):15-9.
37. Bastarache JA, Diamond JM, Kawut SM, **Lederer DJ**, Ware LB, Christie JD. Postoperative Estradiol Levels Associate With Development of Primary Graft Dysfunction in Lung Transplantation Patients. *Gen Med* 2012;9(3):154-65.
38. **Lederer DJ**, Bartels MN, Schluger NW, Brogan F, Jellen P, Thomashow BM, Kawut SM. Sildenafil for chronic obstructive pulmonary disease: a randomized crossover trial. *COPD: Journal of Chronic Obstructive Pulmonary Disease* 2012;9(3):268-75.
39. * Baldwin, MR, Arcasoy SM, Shah A, Sze J, Sonett JR, **Lederer DJ**. Hypoalbuminemia and early mortality after lung transplantation: a cohort study. *Am J Transplant* 2012;12(5):1256-67.
40. Tedford RJ, Hassoun PM, Mathai SC, Girgis RE, Russell SD, Thiemann DR, Cingolani OH, Mudd JO, Borlaug BA, Redfield MM, **Lederer DJ**, Kass DA. Pulmonary capillary wedge pressure augments right ventricular pulsatile loading. *Circulation* 2012;125(2):289-97.
41. *Hook JL, Arcasoy SM, Zimmel D, Bartels M, Kawut SM, **Lederer DJ**. Titrated oxygen requirement and prognostication in idiopathic pulmonary fibrosis. *Eur Respir J* 2012;39(2):359-65.
42. Diamond JM, **Lederer DJ**, Kawut SM, Lee J, Cantu E, Ahya V, Bellamy S, Palmer S, Lama V, Bhorade S, Crespo M, Demissie EJ, Sonett J, Wille K, Orens JB, Shah PD, Weinacker A, Weill D, Kohl B, Deutschman C, Arcasoy S, Shah A, Belperio J, Wilkes D, Reynolds JM, Ware L and Christie JD for the Lung Transplant Outcomes Group. Elevated plasma long pentraxin-3 levels and primary graft dysfunction after lung transplantation for idiopathic pulmonary fibrosis. *Am J Transplant* 2011;11(11):2517-22.
43. **Lederer DJ**, Kawut S, Wickersham N, Winterbottom C, Bhorade S, Palmer S, Lee J, Diamond J, Wille K, Weinacker A, Lama V, Crespo M, Orens J, Sonett J, Arcasoy S, Ware L, Christie J. Obesity and primary graft dysfunction after lung transplantation: the LTOG Obesity Study. *Am J Respir Crit Care Med* 2011;184:1055-61
44. * Lamas DJ, Kawut SM, Bagiella E, Philip N, Arcasoy SM, **Lederer DJ**. Delayed access and survival in idiopathic pulmonary fibrosis: a cohort study. *Am J Respir Crit Care Med* 2011;184:842-7.
45. Kawut SM, Bagiella E, **Lederer DJ**, Shimbo D, Horn EM, Roberts KE, Barr RG, Rosenzweig E, Post W, Palevsky HI, Tracy R, Hassoun PM, Girgis RE. A randomized clinical trial of aspirin and simvastatin for pulmonary arterial hypertension: ASA-STAT. *Circulation* 2011; 123(25):2985-2993.
46. Sims MW, Beers MF, Ahya VN, Kawut SM, Sims KD, **Lederer DJ**, Palmer SM, Wille K, Lama V, Shah PD, Orens JB, Bhorade S, Crespo M, Weinacker A, Demissie E, Bellamy S, Christie JD, Ware LB; for the Lung Transplant Outcomes Group. Effect of single versus bilateral lung transplantation on plasma surfactant protein D levels in idiopathic pulmonary fibrosis. *Chest* 2011; 140(2):489-96.
47. Ginsburg ME, Thomashow BM, Yip CK, DiMango AM, Maxfield RA, Bartels MN, Jellen P, Bulman WA, **Lederer D**, Brogan FL, Gorenstein LA, Sonett JR. Lung volume reduction surgery using the NETT selection criteria. *Ann Thorac Surg* 2011;91(5):1556-60.

48. Diamond JM, Kawut SM, **Lederer DJ**, Ahya VN, Kohl B, Sonett J, Palmer SM, Crespo M, Wille K, Lama VN, Shah PD, Orens J, Bhorade S, Weinacker A, Demissie E, Bellamy S, Christie JD, Ware LB; Lung Transplant Outcomes Group. Elevated plasma clara cell secretory protein concentration is associated with high-grade primary graft dysfunction. *Am J Transplant* 2011;11(3):561-7.
49. Perlman CE, **Lederer DJ**, Bhattacharya J. The micromechanics of alveolar edema. *Am J Respir Cell Mol Biol* 2011;44(1):34-9.
50. Fang A, Studer S, Kawut SM, Ahya VN, Lee J, Wille K, Lama V, Ware L, Orens J, Weinacker A, Palmer SM, Crespo M, **Lederer DJ**, Deutschman CS, Kohl BA, Bellamy S, Demissie E, Christie JD; for the Lung Transplant Outcomes Group. Elevated pulmonary artery pressure is a risk factor for primary graft dysfunction following lung transplantation for idiopathic pulmonary fibrosis. *Chest* 2011;139(4):782-87.
51. Kawut SM, Bagiella E, Shimbo D, **Lederer DJ**, Al-Naamani N, Roberts KE, Barr RG, Post W, Horn EM, Tracy R, Hassoun PM, Girgis RE. Rationale and design of a Phase II clinical trial of aspirin and simvastatin for the treatment of pulmonary arterial hypertension: ASA-STAT. *Contemporary Clinical Trials* 2011;32(2):280-7.
52. Christie JD, Bellamy S, Ware LB, **Lederer D**, Hadjiliadis D, Lee J, Robinson N, Localio AR, Wille K, Lama V, Palmer S, Orens J, Weinacker A, Crespo M, Demissie E, Kimmel SE, Kawut SM. Construct validity of the definition of primary graft dysfunction after lung transplantation. *J Heart Lung Transplant*. 2010 Nov;29(11):1231-9.
53. Jelic S, **Lederer DJ**, Adams T, Padeletti M, Colombo PC, Factor PF, Le Jemtel TH. Vascular inflammation in obesity and sleep apnea. *Circulation* 2010;121(8):1014-21.
54. **Lederer DJ**, Enright PL, Kawut SM, Hoffman EA, Hunninghake G, van Beek EJR, Austin JHM, Jiang R, Lovasi GS, Barr RG. Cigarette smoking is associated with subclinical parenchymal lung disease: The MESA-Lung Study. *Am J Respir Crit Care Med* 2009;180(5):407-14.
55. **Lederer DJ**, Wilt JS, D'Ovidio F, Bacchetta M, Shah L, Ravichandran S, Lenoir J, Klein B, Sonett JR, Arcasoy SM. Obesity and underweight are associated with an increased risk of death after lung transplantation. *Am J Respir Crit Care Med* 2009;180(9):887-95.
56. Milite F#, **Lederer DJ**#, Weingarten JA, Fani P, Mooney AM, Basner RC. Quantification of single-breath lung volume underestimates rebreathed lung volume in emphysema. *Respir Physiol Neurobiol* 2009; 165(2-3):215-20. #Equal contribution
57. Zisman DA, Kawut SM, **Lederer DJ**, Belperio JA, Lynch JP, Schwarz MI, Tayek JA, Reuben DB, Karlamangla AS. Serum albumin concentration and waiting list mortality in idiopathic interstitial pneumonia. *Chest* 2009; 135(4):929-35.
58. Kawut SM, Okun J, Shimbo D, **Lederer DJ**, De Andrade J, Lama V, Milstone A, Ware LB, Weinacker A, Demissie E, Christie JD. Soluble P-selectin and the risk of primary graft dysfunction after lung transplantation. *Chest* 2009;136(1):237-44.
59. Christie JD, Shah CV, Kawut SM, Mangalmurti N, **Lederer DJ**, Sonett JR, Ahya VN, Palmer SM, Wille K, Lama V, Shah PD, Shah A, Weinacker A, Deutschman CS, Kohl BA, Demissie E, Bellamy S, Ware LB, for the Lung Transplant Outcomes Group : Plasma levels of receptor for advanced glycation end-products (sRAGE), blood transfusion, and risk of primary graft dysfunction. *Am J Respir Crit Care Med* 2009;180(10):1010-5.

60. Celik MR, **Lederer DJ**, Wilt J, Eser D, Baccetta M, D'Ovidio F, Sonett JR, Arcasoy SM. Tacrolimus and azathioprine versus cyclosporine and mycophenolate mofetil after lung transplantation: a retrospective cohort study. *J Heart Lung Transplant* 2009;28(7):697-703.
61. **Lederer DJ**, Jelic S, Basner RC, Ishizaka A, Bhattacharya J. Circulating KL-6, a biomarker of lung injury, in obstructive sleep apnea. *Eur Respir J* 2009;33(4):793-6.
62. Jelic S, **Lederer DJ**, Adams T, Padeletti M, Colombo PC, Factor PF, Le Jemtel TH. Endothelial repair capacity and apoptosis are inversely related in obstructive sleep apnea. *Vasc Health Risk Manag* 2009;5:909-20
63. Al-Naamani N, Maarouf OH, Ahya VN, **Lederer DJ**, Mendez JD, Wilt JS, Doyle AM, Rybak D, D'Ovidio F, Sonett JR, Arcasoy SM, Nickolas TL, Kawut SM. Assessment of kidney function in lung transplant candidates. *J Heart Lung Transplant* 2008;27(6):3-41.
64. **Lederer DJ**, Horn EM, Rosenzweig EB, Karmally W, Jahnes M, Barst RJ, Kawut SM. Plasma serotonin levels are normal in pulmonary arterial hypertension. *Pulm Pharmacol Ther* 2008;21(1):112-4.
65. Brodie HD, **Lederer DJ**, Gallardo J, Trivedi S, Burzynski J, Schluger N. Use of an interferon-gamma release assay to diagnose latent tuberculosis infection in the foreign-born. *Chest* 2008;133(4):869-74.
66. Kawut SM, **Lederer DJ**, Wilt JS, D'Ovidio F, Sonett JR, Arcasoy SM, Keshavjee S, Barr M. Outcomes after lung retransplantation in the modern era. *Am J Respir Crit Care Med* 2008;177(1):114-20.
67. **Lederer DJ**, Benn EKT, Barr RG, Wilt JS, Reilly G, Sonett JR, Arcasoy SM, Kawut SM. Racial differences in waiting list outcomes in COPD. *Am J Respir Crit Care Med* 2008;177(4):450-454.
68. Sternberg DI, Shimbo D, Kawut SM, Sarkar J, Hurlitz G, D'Ovidio F, **Lederer DJ**, Wilt JS, Arcasoy SM, Pinsky DJ, D'Armiento JM, Sonett JR. Platelet activation in the postoperative period after lung transplantation. *J Thorac Cardiovasc Surg* 2008;135(3):679-84.
69. Yiming MT, **Lederer DJ**, Sun L, Huertas A, Issekutz AC, Bhattacharya S. Platelets enhance endothelial adhesiveness in high tidal volume ventilation. *Am J Respir Cell Mol Biol* 2008; 39(5):569-75.
70. Al-Naamani N. Maarouf OH, Wilt JS, Bacchetta M, D'Ovidio F, Sonett JR, Arcasoy SM, **Lederer DJ**, Nickolas TL, Kawut SM. The MDRD and prediction of kidney outcomes after lung transplantation. *J Heart Lung Transplant* 2008;27(11):1191-7.
71. **Lederer DJ**, Thomashow BM, Ginsburg ME, Austin JHM, Bartels MN, Yip CK, Jellen PA, Brogan FL, Kawut SM, Maxfield RA, DiMango AM, Simonelli PF, Gorenstein LA, Pearson GDN, Sonett JR. Lung volume reduction surgery for pulmonary emphysema: Improvement in the BODE index after 1 year. *J Thorac Cardiovasc Surg* 2007;133(6): 1434-8.
72. Yegen HA#, **Lederer DJ**#, Barr RG, Wilt JS, Fang Y, Bagiella E, D'Ovidio F, Okun JM, Sonett JR, Arcasoy SM, Kawut SM. Risk factors for venous thromboembolism after lung transplantation. *Chest* 2007;132(2):547-53. #Equal contribution
73. **Lederer DJ**, Arcasoy SM, Barr RG, Wilt JS, Bagiella E, D'Ovidio F, Sonett JR, Kawut SM. Racial and ethnic disparities in idiopathic pulmonary fibrosis: A UNOS/OPTN database analysis. *Am J Transplant* 2006;6(10):2436-42.
74. **Lederer DJ**, Arcasoy SM, Wilt JS, D'Ovidio F, Sonett JR, Kawut SM. Six-minute walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 2006;174(6):659-64.

75. Caplan-Shaw CE, Arcasoy SM, Shane E, **Lederer DJ**, Wilt JS, O'Shea MK, Addesso V, Sonett JR, Kawut SM. Osteoporosis in diffuse parenchymal lung disease. *Chest* 2006;129:140-6.
76. Kawut SM, Horn EM, Berekashvili KK, **Lederer DJ**, Wildlitz AC, Rosenzweig EB, Barst RJ. Selective serotonin reuptake inhibitor use and outcomes in pulmonary arterial hypertension. *Pulm Pharmacol Ther* 2006;19(5):370-4.
77. **Lederer DJ**, Caplan-Shaw CE, O'Shea MK, Wilt JS, Basner RG, Bartels MN, Sonett JR, Arcasoy SM, Kawut SM. Racial and ethnic disparities in survival in lung transplant candidates with idiopathic pulmonary fibrosis. *Am J Transplant* 2006;6:398-403.
78. Yip NH, **Lederer DJ**, Kawut SM, Wilt JS, D'Ovidio F, Wang Y, Dwyer E, Sonett JR, Arcasoy SM. Immunoglobulin G levels before and after lung transplantation. *Am J Respir Crit Care Med* 2006;173(8):917-21.
79. Kawut SM, Reyentovich A, Wilt JS, Anzeck R, **Lederer DJ**, O'Shea MK, Sonett JR, Arcasoy SM. Outcomes of extended donor lung recipients after lung transplantation. *Transplantation* 2005;79:310-6.
80. Batuman O, Go D, Clark LT, Smith EL, Clements P, Feit A, **Lederer D**. Relationship between cytokine levels and coronary artery disease in women. *Heart Disease* 2001;3:80-4.

B. Case Reports

1. **Lederer DJ**, Kawut SM, Sonett JR, Vakiani E, Seward SL Jr, White JG, Wilt JS, Marboe CC, Gahl WA, Arcasoy SM. Successful bilateral sequential lung transplantation for pulmonary fibrosis associated with the Hermansky-Pudlak Syndrome. *J Heart Lung Transplant* 2005;24:1697-9.

C. Books and Chapters

1. * Lamas DJ, **Lederer DJ**. Book Chapter: Lung Transplantation for Idiopathic Pulmonary Fibrosis. In: Meyer K & Nathan S, Eds. *Idiopathic Pulmonary Fibrosis: A Comprehensive Clinical Guide*, Humana Press, Springer, 2014.

D. Reviews and editorials

Reviews

1. Norfolk SG, **Lederer DJ**, Tapson VF. Lung Transplantation and atrial septostomy in pulmonary arterial hypertension. *Clin Chest Med* 2013;34(4):857-65.
2. * Hook J, **Lederer DJ**. Selecting lung transplant candidates: where do current guidelines fall short? *Expert Rev Respir Med* 2012;6(1):51-61.
3. Patel N, **Lederer DJ**, Borczuk A, Kawut SM. Pulmonary hypertension in idiopathic pulmonary fibrosis. *Chest* 2007;132(3):998-1006
4. **Lederer DJ**, Arcasoy SM. Update in surgical therapy for COPD. *Clin Chest Med* 2007; 28(3):639-53.

Editorials

1. **Lederer DJ.** Embracing complex diseases: the case for an IPF biorepository. *Ann Am Thorac Soc* 2014;11(8):1248-9.
2. **Lederer DJ.** Clinical trials in idiopathic pulmonary fibrosis: A framework for moving forward. *Eur Respir J* 2013;42:1446-8.
3. **Lederer DJ,** Yusen R. Disparities and Lung Allocation. *J Heart Lung Transplant* 2013 Jul;32(7):673-4.
4. * Hook JL, **Lederer DJ.** Socioeconomic barriers to lung transplantation: Balancing equity and access. *Am J Respir Crit Care Med* 2012;186:937-9.
5. **Lederer DJ.** Secondary prevention of IPF: Catching the horse still in the barn. *Am J Respir Crit Care Med* 2012;185(7):697-9.
6. **Lederer DJ.** Translational research in lung transplantation: How do we get from mouse to human? *Am J Transplant* 2012;12(2):281-2.
7. **Lederer DJ,** Arcasoy SM. Two, one, or none for chronic obstructive pulmonary disease: Who decides and how? *Am J Respir Crit Care Med* 2011;184(11):1226-7.

Workshops and Guidelines

1. Weill D, Benden C, Corris PA, Dark JH, Duane Davis R, Keshavjee S, **Lederer DJ,** Mulligan MJ, Alexander Patterson G, Singer LG, Snell GI, Verleden GM, Zamora MR, Glanville AR. A consensus document for the selection of lung transplant candidates: 2014-An update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. *J Heart Lung Transplant.* 2015; 23(1):1-15.
2. Rosas IO, Dellaripa PF, **Lederer DJ,** Khanna D, Young LR, Martinez FJ. NHLBI Workshop on the Primary Prevention of Chronic Lung Disease: Interstitial Lung Disease. *Ann Am Thorac Soc* 2014;11 Suppl 3:S169-77.

Letters

1. **Lederer DJ,** Jelic S, Basner RC, Bhattacharya J. Is obstructive sleep apnea a cause of idiopathic pulmonary fibrosis? *Arch Pathol Lab Med* 2012;136(5):470.

Audiovisual/Media

Radio Media Tour for PFF (Nov 21 and 24, 2014 with various air dates)

- The Morning Show, with Jim Berni (WNPQ-FM, Akron, OH)
- The Morning Show with Nelson Hunter (WVNU-FM, Cincinnati, OH)
- Dan & Mike in the Morning (WBEX-AM, Columbus, OH)
- The Lunch Counter (WYYZ-AM, Atlanta)
- Page Two (WDBL-AM, Nashville, TN)
- It's Your Health (National)
- Breakfast with Bob (WAMV-AM, Roanoke, VA)
- Ask Mom RN Show (National)
- Ron & Corey Morning Show (KLTF-AM, Minneapolis, MN)
- News Segment (KETR-AM, Dallas TX)
- Good Mornings (WFIN, Toledo, OH)

Lederer CV

Page 20

News Segment (KULP-AM, Houston TX)
The 2-o'clock Show (KPQ-AM, Seattle WA)
Driving you Home with JR (WKUL-FM, Birmingham, AL)
AM Ocala Live (WOCA-AM, Orlando, FL)
The Morning Report (KSYS-AM, Kansas City, MO)
Community Spotlight (KXEN-AM, St. Louis, MO)

www.pfdoc.org Founder, Patient Education Website & Blog about Pulmonary Fibrosis

2013 PILOT Mini-Symposium: http://www.pilotforipf.org/2013_mini_symposium.php

@davidlederer Twitter account

May 18, 2014 Expert Commentary on pirfenidone/nintedanib in IPF, Health Day, "2 Drugs Offer Hope for Fatal Lung Disease", <http://bit.ly/1rH3AiT>

Dec 16, 2013 Expert Commentary on Lung Transplantation. Reuters Health/Medscape, "Similar Lung Transplant Waitlist Mortality for Children and Adults", Will Boggs MD, <http://www.medscape.com/viewarticle/817911>

July 27, 2011 Expert Commentary on Research in Lung Transplantation. National Public Radio, Connecticut affiliate station WNPR, "Four Failing Lungs", *Where We Live*, Host: John Dankosky. <http://www.yourpublicmedia.org/content/wnpr/where-we-live-four-failing-lungs>

Feb. 28, 2008 Expert Commentary on Racial Disparities in Lung Transplantation. WOL 1450 AM, Washington D.C., Host: Darrell Greene